LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) — Enochian BioSciences (the Company) announced today that it has received a US patent for its proprietary cancer treatment platform that could potentially be used to induce lifelong remission in some of the deadliest solids tumors of the world.

In addition, Dr. Anahid Jewett, Professor and Director of the Laboratory of Tumor Immunology at UCLA, a leader in the field, presented key preclinical animal and laboratory proof-of-concept studies of the Company’s product candidate for treating pancreatic cancer in a humanized mouse model by hu-BLT ( ENOB-DC-11), which have yielded positive and promising results (Link to Investor deck.) Other IND-enabling studies are ongoing. If results continue to remain positive, the company believes it may be able to file a pre-IND application with the FDA by early to mid-2023, followed by IND filing and human trials scheduled for late 2023 or early are planned for 2024.

The company hopes to expand its oncology treatment platform to product candidates that may include triple negative breast cancer, glioblastoma and/or renal cell carcinoma.

“We are incredibly pleased to have received this patent for Enochian’s allogeneic cell and gene therapy cancer treatment platform, especially following encouraging early study results,” said Dr. Mark Dybul, CEO of Enochian. “This technology could be transformative for oncology and the treatment of some of the world’s deadliest cancers, including pancreatic cancer, which has a five-year survival rate of only five to 10 percent. Because therapeutic options are few, we hope to fast-track designation to potentially provide expedited access for people with pancreatic cancer.

dr Anahid Jewett, Enochian’s Chief Oncology Associate, said: “The initial results of my studies have been very encouraging and I look forward to bringing this important…